PRMT3, compound 4. Here, we report comprehensive structure−activity relationship 23 studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and 24 evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated 25 in the discovery of 4 and other highly potent (IC 50 values: ∼10−36 nM), selective, and cell-26 active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37) . In addition, we 27 generated compounds that are very close analogs of these potent inhibitors but displayed 28 drastically reduced potency as negative controls (compounds 49−51). 37 plays a role in ribosome biosynthesis. However, the molecular 38 mechanism by which PRMT3 influences ribosomal biosyn-39 thesis remains unclear. 4 Very recently, an extraribosomal 40 complex comprising PRMT3, rpS2, and human programmed 41 cell-death 2-like (PDCD2L) protein was identified. 5 While 42 PRMT3 is localized exclusively in the cytoplasm, 6 it has been 43 shown that in cells treated with palmitic acid or T0901317 (a 44 liver X receptor α (LXRα) agonist), PRMT3 colocalizes with 45 LXRα in the cell nucleus, regulating hepatic lipogenesis. MCF-7 cells suggests that this interaction is likely to be an Our group embarked on research efforts to discover potent, 76 selective, and cell-active inhibitors of PRMT3 as chemical tools 77 for better understanding of biology and function of this 78 understudied protein methyltransferase. We previously re-79 ported the discovery of a novel allosteric binding site of 80 PRMT3 and the first selective, allosteric inhibitors of PRMT3 f1 81 (compounds 1−3, Figure 1 ) and subsequently disclosed the 82 discovery of SGC707 (4) (Figure 1 ), a highly potent, selective, 83 and cell-active allosteric inhibitor of PRMT3. 20−22 Here, we 84 describe the design and synthesis of a large set of novel analogs 85 and evaluation of these compounds in biochemical, selectivity, 86 and cellular assays. This comprehensive structure−activity 87 relationship (SAR) study resulted in the identification of 88 multiple highly potent, selective, and cell-active allosteric 89 inhibitors of PRMT3 including compound 4.
■ RESULTS AND DISCUSSION
91 Our earlier efforts resulted in the identification of selective 92 small-molecule inhibitors of PRMT3 (compounds 2 and 3) 93 starting from a hit, compound 1 ( Figure 1 ). 20,21 X-ray crystal 94 structures of 1 and 2 in complex with PRMT3 were obtained 95 and showed that these inhibitors occupied a novel allosteric 96 binding site (PDB ID: 3SMQ and 4HSG). These cocrystal 97 structures revealed that the left-hand side (LHS) bicyclic 98 benzothiadiazole moiety fits tightly in the allosteric pocket and 99 the middle nitrogen atom forms a hydrogen bond with T466 f2 100 ( Figure 2 ). The urea linker is located at the entrance of the 101 cavity and forms hydrogen bonds with the guanidine of R396 102 and the carboxylate of E422 (Figure 2 potent as compared to 3 (Table 1) . Therefore, the isoquinoline As the 6-substituted isoquinoline is an optimal LHS bicycle, 142 we then turned our attention to optimizing the RHS moiety of 143 the scaffold. We first revisited saturated aliphatic groups as the t2 144 RHS functionality inspired from our initial studies (Table   t2 145 2). suggested that there is room in the binding pocket to tolerate a 254 relatively small substituent at the 1-, 3-, 7-, and 8-positions of 255 the isoquinoline ring system. Our structural analysis also 256 suggested that a substituent at the 4-and 5-positions of the 257 isoquinoline ring would not be tolerated. Therefore, we 258 designed and synthesized the corresponding substituted 259 isoquinoline analogs (compounds 36−40) to determine t5 260 whether potency could further be enhanced (Table 5) . For 261 example, compounds 36 and 37 featuring small 7-fluoro and 7-262 methyl substituents were prepared. Compound 36 showed 263 similar potency as 4, while 37, which has a slightly larger 264 methyl substituent, was around 2-fold less potent. Compound 265 38, however, displayed significant potency loss (about 10-fold), 266 indicating that the methyl group at the 1-position of the 267 isoquinoline ring is not preferred. Interestingly, the 3-fluoro 268 substituted analog 39 displayed almost 2-fold higher potency 269 with IC 50 of 10 ± 1 nM. This result suggests that the electronic 270 modulation of the isoquinoline ring by a fluoro group does not 271 have significant impact on the hydrogen bonding ability of the The substituted 6-amino isoquinoline derivatives used for 294 the synthesis of compounds 36−40 (Table 5) were not 295 commercially available. Therefore, we devised synthetic routes 296 and prepared these substituted 6-amino isoquinolines as shown 
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Article 308 reactions (Scheme 2A). The 3-fluoro-6-aminoisoquinoline 309 (47) was synthesized starting from the commercially available 310 3-amino-6-bromoisoquinoline in two steps via the Balz− 311 Schiemann reaction 23, 24 followed by an aryl amination 312 (Scheme 2B). As shown in Scheme 2C, 6-amino-8-313 chloroisoquinoline (48) was prepared in six steps. The 314 commercially available 5-aminoisoquinoline was first acetylated 315 and then chlorinated to install a chloro group at the 8-position. 316 Bromination at the 6-position was achieved by using 317 dibromoisocyanuric acid. Deacetylation followed by reductive 318 diazotization resulted in 6-amino-8-chloroisoquinoline (48) 319 (Scheme 2C). Intermediates 44−48 were then used to prepare 320 compounds 36−40 according to the synthetic route outlined 321 in Scheme 1.
322
In addition, we designed and synthesized several close 323 analogs of compound 4 to serve as negative controls for 324 chemical biology studies. As described earlier, the middle urea 325 region of these PRMT3 inhibitors forms the key hydrogen-326 bonding interactions with E422 of PRMT3. We therefore 327 predicted that taking either of these hydrogen-bonding 328 interactions away by methylating either nitrogen atom of the 329 urea would drastically decrease PRMT3 inhibition. Indeed, as t6 330 shown in After filtration, all solvents were removed under reduced pressure, and 459 the residue was purified by column chromatography on silica gel to 460 afford title compound (5) (31 mg, 29% yield). 1 
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Article 477 product, which was then purified by flash column chromatography to 478 yield desired compound as white solid (39 mg, 25%). 1 1-(2-Oxo-2-(piperidin-1-yl)ethyl)-3-(quinazolin-7-yl)urea (7). To 484 a solution of quinazolin-7-amine (73 mg, 0.5 mmol, 1.0 equiv) in 485 DMF (1.5 mL) was added CDI (90 mg, 0.55 mmol, 1.1 equiv), and 486 the resulting mixture was stirred for 8 h at rt. 2-Amino-1-piperidin-1-487 ylethanone hydrochloride salt (134 mg, 0.75 mmol, 1.5 equiv) was 488 then added followed by Hunig's base (131 μL, 0.75 mmol, 1.5 equiv). 489 After being stirred for 18 h at rt, the resulting mixture was diluted with 490 water (25 mL) and extracted with EtOAc (3 × 25 mL). Combined 491 organic layers were dried over sodium sulfate and concentrated under 492 reduced pressure to give crude product, which was then purified by 493 flash column chromatography to yield desired compound (10 mg, 494 6%). 1 
1-(Isoquinolin-7-yl)-3-(2-oxo-2-(piperidin-1-yl)ethyl)urea (8).
To 500 a solution of isoquinolin-7-amine (50 mg, 0.347 mmol) in DMF (1.6 501 mL) at room temperature was added CDI (84 mg, 0.520 mmol). The 502 resulting solution was stirred for 12 h prior to the addition of 2-503 amino-1-(piperidin-1-yl)ethan-1-one (99 mg, 0.694 mmol) and 504 stirred for a further 6 h. Following dilution with water (20 mL), 505 the aqueous layer was extracted with EtOAc (3 × 20 mL), and the 506 combined organic extracts were dried with anhydrous sodium sulfate. 507 After filtration, all solvents were removed under reduced pressure, and 508 the residue was purified by column chromatography on silica gel to 509 afford title compound (8) (45 mg, 42% yield). 
516
General Procedures for the Preparation of Compounds 9− 517 14 in Table 2 . Compounds 9−14 shown in Table 2 were prepared 518 according general procedures described below. To a solution of 519 isoquinolin-6-amine (1.0 equiv) and triethylamine (TEA) (2 equiv) in 520 DMF (1 mL/0.347 mmol) was added CDI (1.5 equiv), and the 521 reaction mixture was allowed to stir at 25°C for 4 h. To the reaction 522 mixture was then added the corresponding amine (2 equiv), and the 523 mixture was allowed to stir for additional 1 h. Then 50 mL of water 524 and 50 mL of EtOAc were added to the reaction mixture. After 525 extraction, the organic layer was washed with brine, dried over 526 anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue 527 was purified by column chromatography on silica gel eluting with 0− 528 5% MeOH in DCM to give the product. Tables 3 and 4 . Synthesis of (Isoquinolin-6-ylcarbamoyl)glycine 1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-(isoquinolin-6-yl)urea (15).
604
The reaction mixture was purified by HPLC to give pure product 5, 156.7, 149.3, 146.9, 145.6, 142.1, 133.3, 132.1, 125.4, 619 124.2, 112.4, 48.1, 47.4, 42.5, 29.7, 28.5, 28.3, 27.8 1-(2-(4,4-Difluoropiperidin-1-yl)-2-oxoethyl)-3-(isoquinolin-6-yl)-622 urea (17). The title compound was obtained as a white solid (mono-623 TFA salt, 51 mg, 66%). 5, 156.8, 149.3, 147.0, 145.7, 628 142.1, 132.2, 125.3, 124.3, 122.9, 112.5, 111.2, 42.6, 40.3, 35.1, 34.6 N-Cyclopropyl-2-(3-(isoquinolin-6-yl)ureido)acetamide (24). The 676 title compound was obtained as a white solid (58 mg, 78%). 1H), 7.59 (dd, J = 8.9, 2.1 Hz, 1H), 4.15 (p, J = 6.7 Hz, 1H), 3.88 (s, 688 2H), 2.00−1.89 (m, 2H), 1.73 (s, 2H), 2H), 1.49 (dq, 689 J = 14.4, 8.3, 7.5 Hz, 2H 1-(2-(Isoindolin-2-yl)-2-oxoethyl)-3-(isoquinolin-6-yl)urea (33).
733
The title compound was obtained as a white solid (42 mg, 73% 1-(7-Methylisoquinolin-6-yl)-3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-826 urea (37) (Scheme 2A; Table 5 ). The same procedures as above were 827 used for the synthesis of 1-(7-methylisoquinolin-6-yl)-3-(2-oxo-2- four steps) was repeated to obtain the title compound 39 (6 mg, 5% 
